AMP886 / Amplia Therap, Cancer Therapeutics CRC - LARVOL DELTA

AMPLIA RECEIVES R&D TAX REBATE TOTALLING $3.77 MILLION (Amplia Therapeutics Press Release) - "The refund relates to expenditure incurred in R&D activities associated with the Company’s FAK inhibitors, narmafotinib (AMP945) and AMP886....The funds will contribute to the further progression of both the ACCENT and AMPLICITY clinical trials of narmafotinib along with additional supporting R&D activities."

Commercial • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Amplia receives R&D Tax Rebate (Amplia Therapeutics Press Release) - "Amplia has today announced that it has received a Research and Development Tax Incentive Refund of$3,177,718 for the 2023/2024 financial year...The refund relates to expenditure incurred in research and development associated with the Company’s FAK inhibitors, narmafotinib (AMP945) and AMP886, and are primarily related to the Company’s ongoing Phase 1b/2a clinical trial of narmafotinib in advanced pancreatic cancer patients....The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5-48.5% of eligible expenditure on research and development activities."

Financing • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

"#AMPLIA and #CRUK Agree to Amend Licence Terms for #AMP886 $ATX https://t.co/UpANSBdzoS" (@1stOncology)

AMPLIA and CRUK Agree to Amend Licence Terms for AMP886 (Amplia Therapeutics Press Release) - "Amplia Therapeutics Limited...wishes to advise that it has negotiated an amendment to its Licence Agreement for the Company’s focal adhesion kinase (FAK) asset AMP886...CRUK has now agreed to extend the deadline for filing an IND or commencing a Phase 1 trial of AMP886 until 31 December 2023."

IND • Licensing / partnership • Oncology